Annual FCF
$3.67 B
+$269.60 M+7.93%
31 December 2023
Summary:
Regeneron Pharmaceuticals annual free cash flow is currently $3.67 billion, with the most recent change of +$269.60 million (+7.93%) on 31 December 2023. During the last 3 years, it has risen by +$1.66 billion (+83.06%). REGN annual FCF is now -43.83% below its all-time high of $6.53 billion, reached on 31 December 2021.REGN Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
$1.05 B
+$906.20 M+633.26%
30 September 2024
Summary:
Regeneron Pharmaceuticals quarterly free cash flow is currently $1.05 billion, with the most recent change of +$906.20 million (+633.26%) on 30 September 2024. Over the past year, it has increased by +$134.90 million (+14.75%). REGN quarterly FCF is now -68.01% below its all-time high of $3.28 billion, reached on 30 September 2021.REGN Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
$3.32 B
+$134.90 M+4.24%
30 September 2024
Summary:
Regeneron Pharmaceuticals TTM free cash flow is currently $3.32 billion, with the most recent change of +$134.90 million (+4.24%) on 30 September 2024. Over the past year, it has dropped by -$1.04 billion (-23.85%). REGN TTM FCF is now -58.17% below its all-time high of $7.94 billion, reached on 31 March 2022.REGN TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
REGN Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +7.9% | +14.8% | -23.9% |
| 3 y3 years | +83.1% | -68.0% | -38.3% |
| 5 y5 years | +102.4% | +140.9% | +66.4% |
REGN Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -43.8% | +83.1% | -68.0% | +338.3% | -58.2% | +31.4% |
| 5 y | 5 years | -43.8% | +102.4% | -68.0% | +338.3% | -58.2% | +109.8% |
| alltime | all time | -43.8% | +1944.0% | -68.0% | +338.3% | -58.2% | +1182.7% |
Regeneron Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.05 B(+633.3%) | $3.32 B(+4.2%) |
| June 2024 | - | $143.10 M(-89.4%) | $3.18 B(-19.0%) |
| Mar 2024 | - | $1.35 B(+74.0%) | $3.93 B(+7.1%) |
| Dec 2023 | $3.67 B(+7.9%) | $776.20 M(-15.1%) | $3.67 B(-15.9%) |
| Sept 2023 | - | $914.40 M(+2.9%) | $4.36 B(+45.1%) |
| June 2023 | - | $888.50 M(-18.4%) | $3.00 B(+18.9%) |
| Mar 2023 | - | $1.09 B(-25.8%) | $2.53 B(-25.6%) |
| Dec 2022 | $3.40 B(-48.0%) | $1.47 B(-433.3%) | $3.40 B(-18.1%) |
| Sept 2022 | - | -$440.40 M(-207.2%) | $4.15 B(-47.3%) |
| June 2022 | - | $410.80 M(-79.0%) | $7.87 B(-0.8%) |
| Mar 2022 | - | $1.96 B(-11.6%) | $7.94 B(+21.5%) |
| Dec 2021 | $6.53 B(+225.9%) | $2.22 B(-32.4%) | $6.53 B(+21.3%) |
| Sept 2021 | - | $3.28 B(+586.0%) | $5.38 B(+217.8%) |
| June 2021 | - | $478.20 M(-13.6%) | $1.69 B(-16.5%) |
| Mar 2021 | - | $553.20 M(-48.3%) | $2.03 B(+1.3%) |
| Dec 2020 | $2.00 B(+0.2%) | $1.07 B(-362.5%) | $2.00 B(+26.6%) |
| Sept 2020 | - | -$407.50 M(-150.1%) | $1.58 B(-34.8%) |
| June 2020 | - | $813.50 M(+54.1%) | $2.43 B(+42.2%) |
| Mar 2020 | - | $527.90 M(-18.6%) | $1.71 B(-14.7%) |
| Dec 2019 | $2.00 B(+10.4%) | $648.40 M(+48.9%) | $2.00 B(+0.3%) |
| Sept 2019 | - | $435.60 M(+364.9%) | $2.00 B(+4.7%) |
| June 2019 | - | $93.70 M(-88.6%) | $1.91 B(-9.0%) |
| Mar 2019 | - | $822.70 M(+27.9%) | $2.10 B(+15.6%) |
| Dec 2018 | $1.81 B(+75.2%) | $643.30 M(+85.5%) | $1.81 B(+11.3%) |
| Sept 2018 | - | $346.70 M(+22.7%) | $1.63 B(-0.5%) |
| June 2018 | - | $282.60 M(-47.6%) | $1.64 B(+29.0%) |
| Mar 2018 | - | $539.40 M(+17.4%) | $1.27 B(+22.6%) |
| Dec 2017 | $1.03 B(+6.2%) | $459.30 M(+29.3%) | $1.03 B(+26.9%) |
| Sept 2017 | - | $355.18 M(-515.8%) | $815.17 M(-17.9%) |
| June 2017 | - | -$85.42 M(-128.0%) | $992.46 M(-25.9%) |
| Mar 2017 | - | $305.44 M(+27.3%) | $1.34 B(+37.4%) |
| Dec 2016 | $974.00 M(+49.2%) | $239.97 M(-54.9%) | $974.00 M(+16.2%) |
| Sept 2016 | - | $532.47 M(+104.3%) | $838.08 M(-20.4%) |
| June 2016 | - | $260.66 M(-541.0%) | $1.05 B(+30.0%) |
| Mar 2016 | - | -$59.10 M(-156.8%) | $809.63 M(+24.0%) |
| Dec 2015 | $652.85 M(+55.7%) | $104.04 M(-86.1%) | $652.85 M(+3.7%) |
| Sept 2015 | - | $746.75 M(+4063.0%) | $629.44 M(-2021.0%) |
| June 2015 | - | $17.94 M(-108.3%) | -$32.77 M(-115.3%) |
| Mar 2015 | - | -$215.89 M(-367.7%) | $214.84 M(-48.8%) |
| Dec 2014 | $419.43 M(-3.0%) | $80.63 M(-4.6%) | $419.43 M(-24.0%) |
| Sept 2014 | - | $84.55 M(-68.2%) | $551.55 M(+4.5%) |
| June 2014 | - | $265.54 M(-2450.9%) | $527.76 M(+48.3%) |
| Mar 2014 | - | -$11.29 M(-105.3%) | $355.93 M(-17.7%) |
| Dec 2013 | $432.27 M(-448.7%) | $212.75 M(+250.1%) | $432.27 M(+45.3%) |
| Sept 2013 | - | $60.76 M(-35.2%) | $297.54 M(+32.7%) |
| June 2013 | - | $93.71 M(+44.1%) | $224.15 M(+472.0%) |
| Mar 2013 | - | $65.05 M(-16.6%) | $39.19 M(-131.6%) |
| Dec 2012 | -$123.95 M(-37.7%) | $78.02 M(-717.8%) | -$123.95 M(-53.0%) |
| Sept 2012 | - | -$12.63 M(-86.2%) | -$263.58 M(-14.0%) |
| June 2012 | - | -$91.25 M(-7.0%) | -$306.58 M(+16.0%) |
| Mar 2012 | - | -$98.10 M(+59.2%) | -$264.25 M(+32.9%) |
| Dec 2011 | -$198.90 M(>+9900.0%) | -$61.61 M(+10.7%) | -$198.90 M(-5.5%) |
| Sept 2011 | - | -$55.63 M(+13.7%) | -$210.41 M(+1268.5%) |
| June 2011 | - | -$48.91 M(+49.4%) | -$15.38 M(+1623.7%) |
| Mar 2011 | - | -$32.75 M(-55.2%) | -$892.00 K(+91.0%) |
| Dec 2010 | -$467.00 K(-99.7%) | -$73.11 M(-152.4%) | -$467.00 K(-111.9%) |
| Sept 2010 | - | $139.40 M(-504.9%) | $3.93 M(-102.3%) |
| June 2010 | - | -$34.43 M(+6.5%) | -$167.63 M(+1.9%) |
| Mar 2010 | - | -$32.32 M(-53.0%) | -$164.57 M(-2.9%) |
| Dec 2009 | -$169.55 M(+36.8%) | -$68.72 M(+113.7%) | -$169.55 M(+11.2%) |
| Sept 2009 | - | -$32.15 M(+2.5%) | -$152.41 M(-10.9%) |
| June 2009 | - | -$31.38 M(-15.9%) | -$171.13 M(+22.0%) |
| Mar 2009 | - | -$37.30 M(-27.7%) | -$140.30 M(+13.2%) |
| Dec 2008 | -$123.94 M | -$51.58 M(+1.4%) | -$123.94 M(+284.0%) |
| Sept 2008 | - | -$50.87 M(+9234.7%) | -$32.28 M(-1106.7%) |
| June 2008 | - | -$545.00 K(-97.4%) | $3.21 M(-302.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | -$20.94 M(-152.2%) | -$1.58 M(-117.7%) |
| Dec 2007 | $8.93 M(-56.0%) | $40.09 M(-360.4%) | $8.93 M(-57.4%) |
| Sept 2007 | - | -$15.39 M(+188.6%) | $20.93 M(+0.3%) |
| June 2007 | - | -$5.33 M(-48.9%) | $20.88 M(+301.7%) |
| Mar 2007 | - | -$10.44 M(-120.0%) | $5.20 M(-74.4%) |
| Dec 2006 | $20.26 M(-157.5%) | $52.09 M(-437.2%) | $20.26 M(-138.9%) |
| Sept 2006 | - | -$15.45 M(-26.5%) | -$52.03 M(-2.4%) |
| June 2006 | - | -$21.02 M(-553.7%) | -$53.30 M(-14.6%) |
| Mar 2006 | - | $4.63 M(-122.9%) | -$62.40 M(+77.0%) |
| Dec 2005 | -$35.26 M(+52.8%) | -$20.20 M(+20.8%) | -$35.26 M(+23.3%) |
| Sept 2005 | - | -$16.71 M(-44.5%) | -$28.59 M(+60.8%) |
| June 2005 | - | -$30.12 M(-194.8%) | -$17.77 M(-162.9%) |
| Mar 2005 | - | $31.77 M(-334.9%) | $28.26 M(-222.4%) |
| Dec 2004 | -$23.08 M(-35.5%) | -$13.53 M(+129.3%) | -$23.08 M(-41.2%) |
| Sept 2004 | - | -$5.90 M(-137.1%) | -$39.27 M(-256.8%) |
| June 2004 | - | $15.91 M(-181.3%) | $25.05 M(-168.6%) |
| Mar 2004 | - | -$19.57 M(-34.1%) | -$36.55 M(+2.1%) |
| Dec 2003 | -$35.79 M(-75.3%) | -$29.71 M(-150.9%) | -$35.79 M(-31.5%) |
| Sept 2003 | - | $58.42 M(-227.9%) | -$52.27 M(-63.4%) |
| June 2003 | - | -$45.69 M(+142.9%) | -$142.87 M(+6.9%) |
| Mar 2003 | - | -$18.81 M(-59.3%) | -$133.65 M(-7.8%) |
| Dec 2002 | -$144.89 M(+121.1%) | -$46.20 M(+43.6%) | -$144.89 M(+21.8%) |
| Sept 2002 | - | -$32.17 M(-11.8%) | -$118.95 M(+7.7%) |
| June 2002 | - | -$36.47 M(+21.3%) | -$110.44 M(+29.1%) |
| Mar 2002 | - | -$30.05 M(+48.4%) | -$85.56 M(+30.5%) |
| Dec 2001 | -$65.54 M(+90.5%) | -$20.25 M(-14.4%) | -$65.54 M(+30.5%) |
| Sept 2001 | - | -$23.66 M(+104.1%) | -$50.22 M(+59.0%) |
| June 2001 | - | -$11.59 M(+15.4%) | -$31.59 M(+21.1%) |
| Mar 2001 | - | -$10.04 M(+103.4%) | -$26.09 M(-24.2%) |
| Dec 2000 | -$34.41 M(+79.2%) | -$4.93 M(-1.8%) | -$34.41 M(+49.8%) |
| Sept 2000 | - | -$5.03 M(-17.4%) | -$22.97 M(-14.4%) |
| June 2000 | - | -$6.08 M(-66.9%) | -$26.84 M(-4.7%) |
| Mar 2000 | - | -$18.36 M(-382.4%) | -$28.16 M(+46.7%) |
| Dec 1999 | -$19.20 M(+45.5%) | $6.50 M(-173.0%) | -$19.20 M(-40.0%) |
| Sept 1999 | - | -$8.90 M(+20.3%) | -$32.00 M(+58.4%) |
| June 1999 | - | -$7.40 M(-21.3%) | -$20.20 M(+15.4%) |
| Mar 1999 | - | -$9.40 M(+49.2%) | -$17.50 M(+32.6%) |
| Dec 1998 | -$13.20 M(+61.0%) | -$6.30 M(-317.2%) | -$13.20 M(+200.0%) |
| Sept 1998 | - | $2.90 M(-161.7%) | -$4.40 M(-53.2%) |
| June 1998 | - | -$4.70 M(-7.8%) | -$9.40 M(+8.0%) |
| Mar 1998 | - | -$5.10 M(-304.0%) | -$8.70 M(+6.1%) |
| Dec 1997 | -$8.20 M(-71.6%) | $2.50 M(-219.0%) | -$8.20 M(-28.1%) |
| Sept 1997 | - | -$2.10 M(-47.5%) | -$11.40 M(-32.1%) |
| June 1997 | - | -$4.00 M(-13.0%) | -$16.80 M(-21.5%) |
| Mar 1997 | - | -$4.60 M(+557.1%) | -$21.40 M(-26.0%) |
| Dec 1996 | -$28.90 M(+34.4%) | -$700.00 K(-90.7%) | -$28.90 M(+0.3%) |
| Sept 1996 | - | -$7.50 M(-12.8%) | -$28.80 M(-12.7%) |
| June 1996 | - | -$8.60 M(-28.9%) | -$33.00 M(+22.7%) |
| Mar 1996 | - | -$12.10 M(+1916.7%) | -$26.90 M(+25.1%) |
| Dec 1995 | -$21.50 M(-21.5%) | -$600.00 K(-94.9%) | -$21.50 M(-32.4%) |
| Sept 1995 | - | -$11.70 M(+368.0%) | -$31.80 M(+19.1%) |
| June 1995 | - | -$2.50 M(-62.7%) | -$26.70 M(+36.2%) |
| Mar 1995 | - | -$6.70 M(-38.5%) | -$19.60 M(-28.5%) |
| Dec 1994 | -$27.40 M(-32.0%) | -$10.90 M(+65.2%) | -$27.40 M(-18.5%) |
| Sept 1994 | - | -$6.60 M(-243.5%) | -$33.60 M(-1.8%) |
| June 1994 | - | $4.60 M(-131.7%) | -$34.20 M(-27.7%) |
| Mar 1994 | - | -$14.50 M(-15.2%) | -$47.30 M(+17.4%) |
| Dec 1993 | -$40.30 M(+108.8%) | -$17.10 M(+137.5%) | -$40.30 M(-294.7%) |
| Sept 1993 | - | -$7.20 M(-15.3%) | $20.70 M(-177.5%) |
| June 1993 | - | -$8.50 M(+13.3%) | -$26.70 M(+15.6%) |
| Mar 1993 | - | -$7.50 M(-117.1%) | -$23.10 M(+19.7%) |
| Dec 1992 | -$19.30 M(+147.4%) | $43.90 M(-180.4%) | -$19.30 M(-69.5%) |
| Sept 1992 | - | -$54.60 M(+1014.3%) | -$63.20 M(+634.9%) |
| June 1992 | - | -$4.90 M(+32.4%) | -$8.60 M(+132.4%) |
| Mar 1992 | - | -$3.70 M | -$3.70 M |
| Dec 1991 | -$7.80 M | - | - |
FAQ
- What is Regeneron Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual FCF year-on-year change?
- What is Regeneron Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly FCF year-on-year change?
- What is Regeneron Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals TTM FCF year-on-year change?
What is Regeneron Pharmaceuticals annual free cash flow?
The current annual FCF of REGN is $3.67 B
What is the all time high annual FCF for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual free cash flow is $6.53 B
What is Regeneron Pharmaceuticals annual FCF year-on-year change?
Over the past year, REGN annual free cash flow has changed by +$269.60 M (+7.93%)
What is Regeneron Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of REGN is $1.05 B
What is the all time high quarterly FCF for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly free cash flow is $3.28 B
What is Regeneron Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, REGN quarterly free cash flow has changed by +$134.90 M (+14.75%)
What is Regeneron Pharmaceuticals TTM free cash flow?
The current TTM FCF of REGN is $3.32 B
What is the all time high TTM FCF for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high TTM free cash flow is $7.94 B
What is Regeneron Pharmaceuticals TTM FCF year-on-year change?
Over the past year, REGN TTM free cash flow has changed by -$1.04 B (-23.85%)